Ameritox

Archive for the ‘ Ameritox in The News ’ Category

UNITE holds Shoot Hoops Not Drugs event

June 24, 2016 / Mike Gottfried

So many life lessons can be learned from the game of basketball,” former University of Kentucky basketball player Jeff Sheppard said. “It’s the least I can do to spend some time with the kids in our communities and deliver a message about basketball but a message of hope as well about staying away from drugs and making the right decisions.”

Sheppard along with former UK Wildcat Jarrod Polson joined forces with Operation Unite for the 5th Annual Shoot Hoops Not Drugs event. Over 100 children from across the area came to the event to learn basketball fundamentals and an important message about drug abuse.

“Just the overall message of the camp is just trying to get kids away from the drug scene and how it’s been prevalent in the mountains. Anything to do to prevent that and help those kids and get them on a different path is something I like to do,” Polson said.

UNITE joined together with Ameritox, a company that “the nation’s leader in pain medication monitoring, offering laboratory services and practice management tools to help clinicians coordinate and optimize the care of chronic pain patients,” according to its website.

Ameritox’s director of communications, Lon Wagner, said, “We (Ameritox) wanted to sponsor this event. We’re involved in battling the prescription drug epidemic, and so is Operation Unite. Part of our mission, as we say, is to prevent human tragedy.”

“We want to instill in the kids a couple of things,” Wagner said. “Don’t do drugs that don’t belong to you. Secondly [this camp] is a good, healthy activity. Even if you never end up playing basketball, you’re out here, exercising, getting your heart rate up and doing something positive.”

Sheppard and Polson taught children of all ages the fundamentals of basketball, ranging from basic ball handling skills to defensive stances. This was the final Shoot Hoops Not Drugs camp that Operation UNITE held.

Operation UNITE will also be holding a week long leadership camp at the end of July at the University of Cumberlands.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Josh Silberberg
30 Point Strategies
(202) 304-1546
joshua@30point.com

Ameritox Partners for Third Year with Operation UNITE Youth Basketball Camps Focused on Drug Abuse Prevention

June 10, 2016 / Mike Gottfried

“Shoot Hoops, Not Drugs” summer basketball camps offer rural Kentucky students the necessary skills to help prevent drug misuse and abuse

BALTIMORE, MD. – June 10, 2016 — AmeritoxSM, a national leader in medication monitoring solutions, will sponsor for the third consecutive year a series of basketball camps organized by Kentucky-based Operation UNITE. The camps are headed by former University of Kentucky basketball stars who teach basketball skills that also incorporate anti-drug messages aimed at boosting students’ self-worth.

“By hosting these basketball camps for more than a decade, Operation UNITE has helped instill Eastern Kentucky youth with the self-esteem needed to steer clear of the prescription drug abuse that has devastated their community,” said Scott Walton, Ameritox CEO. “Ameritox is proud to sponsor these camps, because like Operation UNITE, we know that this epidemic can only be stopped by preventing the next generation from succumbing to opioid misuse and abuse.”

Operation UNITE was created by Kentucky Congressman Hal Rogers in 2003 to bring together government, law enforcement and businesses in fighting Kentucky’s rampant drug problems. The camps were created to foster strong deterrents for drug abuse in school-aged children.

Ameritox employees will provide support to Operation UNITE staff at the camps.
 
“We’re grateful to once again have Ameritox’s generous support, but we’re even more grateful that they continue to fight alongside us in the battle to prevent our kids from traveling down the frightening path of drug abuse,” said Nancy Hale, CEO of Operation UNITE.

The five free 2016 camps will be led by former University of Kentucky Final Four MVP Jeff Sheppard. All-SEC Academic Team member Jarrod Polson will join Sheppard for the last three camps. The dates and locations of the camps are:

  • Tuesday, June 14 – Warfield Middle School, Warfield, Martin County
  • Thursday, June 16 – Owsley County High School, Booneville
  • Monday, June 20 – Morgan County High School, West Liberty
  • Tuesday, June 21 – Rodney C. Woods Gym, Wayne County Schools Campus, Monticello
  • Thursday, June 23 – Knott County Sportsplex, 450 Kenny Champion Loop, Leburn

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

About Operation UNITE
Operation UNITE, which stands for Unlawful Narcotics Investigations, Treatment & Education, seeks to fight the drug epidemic by expanding drug awareness and education programs to keep people from using drugs; coordinating drug treatment and outreach programs for those who are already addicted; and operating regional undercover law enforcement task forces for interdiction and prosecution of those dealing drugs.

Visit the UNITE website at: www.operationunite.org

Ameritox Research Confirms Significant Spike in Potential Nonadherence to Opioid Medications

February 22, 2016 / Mike Gottfried

BALTIMORE, Feb. 22, 2016 — AmeritoxSM, a national leader in medication monitoring solutions, presented new research Friday showing a nearly 20-percent increase in the share of patient samples that do not contain the patient’s prescribed opioid medication. Attendees at the American Academy of Pain Medicine (AAPM) Annual Meeting, held in Palm Springs, California, learned that a full 43 percent of patient samples collected over a period of 31 months ending in July 2015 showed potential nonadherence. The 2012 Ameritox National Prescription Drug Report found that 35.9 percent of patient samples showed potential nonadherence.

Samples where a prescribed opioid is not detected raise serious concerns about patient care or the risk of drug diversion – intentional or accidental.

Based on samples collected from more than 447,000 patients between January 2013 and July 2015, the Ameritox data showed that potential nonadherence was greatest among those aged 10-19, at a rate of 62 percent. Though potential nonadherence declined in each decade after that, it remained significant even among those aged 60-69 (potential nonadherence, 39 percent) and those aged 70-79 (potential nonadherence, 37 percent).

“We understand that many patients find it difficult to have conversations with their doctor about their treatment,” said Ameritox Chief Medical Officer Dr. Tom Smith. “Medication monitoring results can help prompt doctor-patient discussions that lead to improved patient care, and also is an important tool in reducing misuse, abuse and diversion of prescription medication.”

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Josh Silberberg
30 Point Strategies
(202) 304-1546
joshua@30point.com

Ameritox Data on ADHD Stimulant Prescriptions Uncovers Significant Rates of Illicit Drug Use and Potential Nonadherence to Drug Regimen

January 18, 2016 / Mike Gottfried

WASHINGTON – January 18, 2016 – AmeritoxSM, a national leader in medication monitoring solutions, presented new research showing that in one out of three samples of patients prescribed stimulants to treat attention-deficit/hyperactivity (ADHD) disorder the prescribed drug was not detected. Members of Ameritox’s Medical Affairs team prepared the data for attendees at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting, held in Washington, where conference organizers highlighted the Ameritox report for attendees.

Based on samples collected from more than 4,000 patients between July 1, 2014 and June 30, 2015, the Ameritox data showed indications that potential nonadherence to prescription stimulants in the treatment of ADHD is associated with elevated rates of illicit drug use as well as non-medical use of opioids and benzodiazepines. In samples where the prescribed stimulant was not detected, THC was present more than 20 percent of the time. Nearly four in ten samples where the prescribed stimulant was not detected tested positive for some combination of a nonprescribed opioid, nonprescribed benzodiazepine, THC and/or cocaine.

In addition, patients being treated for ADHD with prescription stimulants showed high rates of potential nonadherence across all age groups. Patients over the age of 60 showed the lowest rates of potential nonadherence, with 24.4 percent of samples absent the prescribed drug. Patients between ages 20 and 29 had the highest rates of potential nonadherence, as more than 40 percent of all samples collected from patients in that age range tested negative for their prescribed stimulant.

“Even in the best case scenarios,” said Ameritox Chief Medical Officer Dr. Tom Smith, “the potential for diversion or illicit drug use is alarmingly high. The misuse, abuse and diversion of ADHD medications cannot be casually brushed aside when these results suggest that even when the prescribed ADHD medication is found there is a nearly one in four chance that the sample will also test positive for potentially dangerous substances.”

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Josh Silberberg
30 Point Strategies
202-304-1546
josh@30point.com

Ameritox Wins Award for Compliance Training

December 17, 2015 / Mike Gottfried

Respected human capital management firm recognizes value of Ameritox compliance program

BALTIMORE, Dec. 17, 2015 /PRNewswire/ — AmeritoxSM, a national leader in medication monitoring solutions, today announced the “Ameritox STARK Shark Challenge,” a supplement to annual compliance training that focuses on interactions with potential clients, won a bronze medal as part of the 2015 Brandon Hall Group Excellence in Awards for Learning and Development, Talent Management, and Sales and Marketing.

Logo – http://photos.prnewswire.com/prnh/20151217/296848LOGO

“Ameritox’s compliance efforts do not amount to a box we simply check. Our focus ensures responsible expansion of our business, reinforces our mission to strengthen improve patient care and prevent human tragedy, and sets a high standard for our industry,” said Scott Walton, CEO of Ameritox.

Entries for the Brandon Hall Group Excellence Awards were evaluated by a panel of veteran, independent senior industry experts along with Brandon Hall Group senior analysts and executive leadership. The entries were judged based on their ability to fit the need, the design of the program, functionality and innovation.

The Ameritox STARK Shark Challenge was redesigned in 2014 with the help of GP Strategies, a sales and technical training consulting firm, to transform pages of flat text into an engaging scenario that invites participation, questions, and ultimately, deepens understanding of a critical component of the Ameritox compliance program.

“The high quality of work and commitment to driving business results among our award winners never fails to amaze me,” said Rachel Cooke, Chief Operating Officer of Brandon Hall Group and head of the awards program. “But the real winners of this award are Ameritox’s customers and clients because of the innovation and customer focus the company demonstrates.”

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742

Genevieve Rozansky
202-509-0794

Ameritox Applauds Maryland Governor’s Heroin and Opioid Emergency Task Force for Recommending Statewide Use of Medication Monitoring

December 8, 2015 / Mike Gottfried

BALTIMORE, Dec. 8, 2015 /PRNewswire-USNewswire/ — AmeritoxSM, a national leader in medication monitoring solutions, today applauded the Maryland Heroin and Opioid Emergency Task Force, chaired by Maryland Lieutenant Governor Boyd K. Rutherford, for recommending the use of prescription medication monitoring statewide in the Task Force’s final report to Governor Larry Hogan. This recommendation follows examples set by Kentucky, Indiana, Washington and Georgia of requiring some form of medication monitoring for those who are being prescribed opioids for the long-term.

Logo – http://photos.prnewswire.com/prnh/20151208/294145LOGO

“We’re very pleased these leaders clearly recognize that prevention is a crucial part of stopping the opioid epidemic, and medication monitoring remains a key facet of successful prevention,” said Todd Gardner, Chief Operating Officer of Ameritox. “Maryland is served well by the fact that the Task Force understands the importance of prescription medication monitoring as a critical tool in the fight to curb opioid misuse, abuse and diversion.”

The Task Force explains in its final report that medication monitoring “could lead to better health outcomes by detecting possible diversion of prescription opioids or the presence of non-prescribed or illicit drugs in urine samples.” The report cited clinical research from Ameritox, which found that 48 percent of patient samples from Maryland contained a drug that had not been prescribed by the doctor who ordered the drug screening. This percentage reflects the second worst rate in the country, according to Ameritox’s data.

A copy of the final report from the Maryland Heroin and Opioid Emergency Task Force can be found here.

Gardner will testify Wednesday before the Maryland Joint Legislative Committee on Opioid Disorders about how medication monitoring can improve patient outcomes, while preventing tragedy. Additionally, Ameritox’s service PRIUM, a chronic pain medical management company specializing in workers’ compensation, is currently collaborating with Maryland-based Chesapeake Employers Insurance Company on a pilot program. The aim is to identify specific cases of injured workers being prescribed significantly high dosages of opioids and to engage directly with their doctors to help create better patient outcomes. The full results of the program will be announced in the coming months.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring Solutions(SM), Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent human tragedy. Ameritox, headquartered in Baltimore, Md., has a national footprint and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742

Genevieve Rozansky
202-509-0794

Ameritox Service PRIUM Announces Pilot Program With Chesapeake Employers Insurance Company to Improve Patient Outcomes for Workers’ Compensation Patients

November 24, 2015 / Mike Gottfried

BALTIMORE, Nov. 24, 2015 /PRNewswire/ — AmeritoxSM, a national leader in medication monitoring solutions and its service PRIUM, a chronic pain medical management company specializing in workers’ compensation, today announced the creation of a pilot program with Maryland-based Chesapeake Employers Insurance Company to identify specific cases of injured workers being prescribed significantly high dosages of opioids and to engage directly with their doctors to help create better patient outcomes.

Logo – http://photos.prnewswire.com/prnh/20151124/290665LOGO

The pilot program is a direct response to the troubling rate of opioid misuse, abuse and diversion in Maryland, where Ameritox is headquartered. In 2014, Ameritox clinical data identified Maryland among the nation’s 10 worst states in two problem areas: “Non-prescribed drug found,” which translates to a prescription opioid not prescribed to the patient being detected in the collected urine sample, and “one or more illicit drugs found” in patients’ samples.

The goal of the pilot study is for PRIUM’s physician consultants to engage with the physicians treating injured workers to achieve a meaningful reduction in the patients’ morphine equivalent dosages (MED). Chesapeake is identifying patients and physicians for PRIUM. Independent clinical research has shown that gradually and responsibly decreasing an injured worker’s MED amount can lead to overall better health and a return to work.

“Chesapeake’s interest in this program reflects our focus on exploring innovative approaches to reducing the negative impact that opiate overuse and dependence is having on the lives of injured workers and their families,” said Dr. Stephen Fisher, Director of Health Services for Chesapeake.

“All of these cases so far raise significant alarm – each shows potentially excessive opioid prescribing and use,” said Michael Gavin, President of PRIUM. Gavin explains the extent of the problem: “For instance, most state regulations say that 60-100 MED per day is acceptable, but that anything over that greatly increases the risk of drug overdose. These cases all exceed 300 MED per day.”

Preliminary findings of the Ameritox/PRIUM/Chesapeake pilot program were discussed in testimony before the Maryland Inter-Agency Heroin and Opioid Coordinating Council. The two Maryland-based companies came together after discussions that began while providing input to the Heroin and Opioid Emergency Task Force, established by Governor Larry Hogan and headed by Lt. Gov. Boyd Rutherford.

“We’re proud to be working with Chesapeake to help prevent human tragedy and make patients’ lives better, and we’re especially thankful for the attention of leaders in Maryland state government toward fighting the opioid epidemic,” said Todd Gardner, Chief Operating Officer of Ameritox.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has a national footprint and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742

Genevieve Rozansky
202-509-0794

Ameritox Advocate and Former DEA Special Agent to Lead Symposium on Preventing Prescription Opioid and Heroin Abuse in Local Community

October 28, 2015 / Mike Gottfried

BALTIMORE, Oct. 28, 2015 /PRNewswire/ — AmeritoxSM, a national leader in medication monitoring solutions, today announced that Richard A. Tucker, retired Assistant Special Agent in Charge with the Drug Enforcement Administration (DEA), will lead a symposium to empower Cobb County Georgia community members to help prevent prescription opioid and heroin abuse among their loved ones, friends and neighbors.

Logo – http://photos.prnewswire.com/prnh/20151028/281444LOGO

The 5th Annual “Becoming Your Own Advocate” symposium on October 29th is organized by the Davis Direction Foundation and sponsored by WellStar Health Systems, both of Cobb County. Tucker offers symposium attendees a lifetime of experience in preventing and fighting opioid misuse, abuse, and diversion, having served 10 years as a police officer in Cobb County at the beginning of his career, and 25 years with the DEA on assignments in Atlanta, Denver, El Paso, Texas, Los Angeles and Thailand to investigate global drug trafficking operations. He also served in Washington, D.C. as the chief of the DEA’s International Intelligence Program.

The Davis Direction Foundation was created in memoriam of Davis Owen, who to combat stress and anxiety developed a well-hidden prescription painkiller addiction as a teenager. The prescriptions he stole out of his family’s medicine cabinet eventually led Davis to heroin abuse — and to his death in March 2014 of a heroin overdose. The Davis Direction Foundation works one-on-one with individuals and their doctors and family members to tear down the outdated stigmas of opiate addicts and to restructure the long process of drug rehabilitation to recognize and escalate opiate addiction as a severe and all-too-common

“We’re thrilled to have Rick leading this year’s symposium as a Cobb County native, and as someone who has seen firsthand all over the world the fight we’re all fighting,” said Missy Owen, Executive Director of the Davis Direction foundation. “Only by working together as a community – which includes doctors, patients, family members, and law enforcement – are we going to prevent the prescription opioid and heroin abuse that has claimed the lives of too many loved ones, including our son, Davis.”

Cobb County has identified a significant problem with opioid misuse, abuse and diversion: In 2013, a large percentage of the cases handled by a local law enforcement narcotics unit involved prescription painkillers and other drugs.

“With every additional person who gets educated about the triggers and warning signs of prescription opioid and heroin abuse, our chances to prevent more tragedies goes up,” said Tucker. “This is an important gathering that could lead to many more lives being saved.”

Attending “Becoming Your Own Advocate” will offer a powerful and educational understanding of the epidemic in Cobb County. The symposium will take place at 7 p.m. at Marietta First United Methodist Church, 56 Whitlock Ave. SW, in Marietta, GA.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has a national footprint and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742

Genevieve Rozansky
202-509-0794

Ingenuity Health Releases First Research Report On Potential Medication Non-Adherence and Misuse of Opioids and Illicit Drugs among the Seriously Mentally Ill

September 8, 2015 / Mike Gottfried

Research based on urine drug testing focused on exposing the problems associated with
medication non-adherence in those with SMI and how medication monitoring can help

BALTIMORE – Sept. 8 – Ingenuity Health, a service of Ameritox, Ltd., and a leading provider of medication monitoring solutions to behavioral health clinicians, today released its first-ever research report that examines the extent of potential patient non-adherence to antipsychotic medications used to treat serious mental illness (SMI). The report details the harmful effects of non-adherence for patients and society along with the equally pernicious problem of misuse of prescription painkillers and abuse of illicit drugs in patients with SMI.

Based on nearly 23,000 patient samples collected through urine drug monitoring and tested for
the presence of a prescribed antipsychotic, 24.8 percent of samples did not contain the prescribed antipsychotic, 33 percent contained a non-prescribed drug and 19.7 percent contained an illicit drug. Marijuana and non-prescribed benzodiazepines (such as Valium or Xanax) were the most commonly detected illicit drugs and non-prescribed drugs.

“Medication non-adherence, along with the practice of misusing and abusing opioids and the
abuse of illicit drugs, occur too often among people with serious mental illnesses, and pose
serious risks to the health and welfare of these patients, and to those around them,” said Jerry Vaccaro, MD, President of Ingenuity Health. “With these obstacles to long-term health, the more additional insight into adherence that we can provide, the better clinicians can treat and manage their patients and prevent tragedy.”

“We’re publishing these internal results because the consequences of those with serious mentalillness going untreated are enormous for both patients and the communities they live in,” said Scott Walton, CEO of Ameritox. “We also hope that these facts will help public officials, health care workers, community groups, educators and media use this data to address the issues that mental illness creates for patients and for society.”

About Ingenuity Health

As a service of Ameritox℠, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with SMI.

Visit the Ingenuity Health website at: www.ingenuityhealth.com

Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national
epidemic of prescription drug misuse, abuse, and diversion. As a trusted leader in Pain Medication Monitoring Solutions℠, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com

Follow Ameritox on Twitter: www.twitter.com/ameritox

Lon Wagner, Ameritox
Office: 336-387-7742
lon.wagner@ameritox.com

Genevieve Rozansky, 30 Point Strategies
Office: 202-509-0794
genevieve@30point.com

Ingenuity Health Study Reveals Potential Non-Adherence to Antipsychotic Medications Differs Based on Diagnosis

June 24, 2015 / Mike Gottfried

Will Present Clinical Research to Psychopharmacology Community


BALTIMORE – June 24, 2015 – Ameritox’s Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians, today announced new clinical research based on urine drug monitoring samples that revealed that participants who suffer from bipolar disorder and severe depression are more likely to be non-adherent to their prescribed antipsychotic medication than those who suffer from schizophrenia. These results differ from recent literature on non-adherence in those with serious mental illness (SMI).

Medication nonadherence can result in significant barriers to the long-term health of those with SMI.

“This research challenges current notions about medication adherence among those with bipolar disorder and severe depression, but it remains clear that non-adherence is the single greatest threat to long-term health for those who suffer from SMI,” said Tom Smith, M.D., Chief Medical Officer for Ingenuity Health and Ameritox.

Ingenuity Health medical scientists, along with research contributor Dr. Robert Millet, Assistant Medical Director of Carolina Behavioral Care in Raleigh, NC, will present the research in a medical poster titled “Adherence to Treatment With Antipsychotic Medications Among Patients With Schizophrenia, Major Depressive Disorder, or Bipolar Disorder” today at the annual meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami, Fla.

“Simply put, this study shows that we need more vigilance of medications among the seriously mentally ill, especially considering that medication monitoring is the easiest way to improve patient outcomes,” said Dr. Millet. “Although it’s widely accepted that patients with schizophrenia would benefit from medication monitoring, this dataset suggests that patients with bipolar disorder and depression should also be monitored.”

Additionally, Ingenuity Health will present at the ASCP annual meeting a medical poster titled “Evaluation of Cytochrome P450 Phenotypes and Potential Implications in the Treatment of Serious Mental Illness.”

For more information about ASCP and its annual meeting, visit https://www.ascpp.org.

About Ingenuity Health
As part of Ameritox, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness (SMI).

Visit the Ingenuity Health website at: www.ingenuityhealth.com
Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As a trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Genevieve Rozansky
202-509-0794
genevieve@30point.com

Millennium Health to Pay $8.6 Million for Infringing on Ameritox-licensed Patent

April 22, 2015 / Steve Denker

Federal Jury Unanimously Finds that Millennium Health (formerly Millennium Laboratories) Infringed Underlying Patent of Ameritox’s Rx Guardian CD®

BALTIMORE – April 22, 2015 — A federal jury has unanimously found Millennium Health (formerly Millennium Laboratories) to have infringed U.S. Patent No. 7,585,680 (the “‘680 Patent”). The jury awarded Ameritox $8.6 million in damages.

The ‘680 Patent is owned by the Marshfield Clinic, a non-profit healthcare system of hospitals and community care centers in Wisconsin, and exclusively licensed to Ameritox. The jury’s decision upheld the validity of the patent and, along with an earlier court decision, resulted in Millennium’s removal of the infringing features of the RADAR® Report.

Millennium began infringing on the patent by unveiling its RADAR Report with graphed results three weeks after Ameritox launched its Rx Guardian CD® medication monitoring program in May 2011. Millennium continued infringing on the patent by using its RADAR Report with graphed results into 2015.

Ameritox’s Rx Guardian CD service compares a patient’s normalized urine drug monitoring results to a database of patients clinically assessed as adherent. Ameritox’s INSIGHT report displays those results graphically on a bell curve.

Millennium’s RADAR Report compares a patient’s normalized urine drug monitoring results to a database of patients prescribed the same medication – though those patients have not been clinically assessed as adherent. Millennium’s RADAR report displayed those results graphically on a bell curve.

The Chief Judge of the Western District of Wisconsin, William M. Conley, addressed this difference in a pre-trial Summary Judgment Order: “While … shortcomings in the data used in Millennium’s RADAR Report may well make for an inferior product, they do not render the product non-infringing.”

The ‘680 patent covers Ameritox’s Rx Guardian CD service and reports. The Rx Guardian CD display is designed to improve treatment outcomes by giving clinicians more insight into whether a patient may be taking prescribed medications correctly.

“Rx Guardian CD is a highly differentiated offering that brings unique value and insights to our customers,” said Ameritox CEO Scott Walton.  “We are proud that we are the scientific leader in the industry and pleased that the court decision has served to validate that fact.”

After the ‘680 Patent was issued by the U.S. Patent and Trademark Office, Millennium twice sought reexamination of it in an effort to have it invalidated.  On both occasions, the Patent Office affirmed its previous decision on patentability.

This is the second jury within a year that has ruled in favor of Ameritox against Millennium. In June 2014, a judge and jury in the Middle District Court of Florida, found Millennium in violation of the federal Anti-Kickback Statute and Stark laws for offering doctors free Point-of-Care Testing cups, which was found to constitute illegal inducements for business.  In that case, Ameritox was awarded more than $11 million in damages.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As a trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Genevieve Rozansky
202-509-0794
genevieve@30point.com

Ameritox Partners With MVP Health Care in New York and Vermont

June 2, 2014 / Steve Denker

BALTIMORE, June 2, 2014 /PRNewswire/ — AmeritoxSM, the nation’s leader in medication monitoring solutions, today announced a new agreement with MVP Health Care® to provide urine drug monitoring services to MVP plan members in New York, Vermont and New Hampshire.

Ameritox’s services will be a covered benefit in all health plans offered by MVP, including Medicare and Medicaid.

“Ensuring the safety and well-being of our members is important to us,” stated Dr. Carl Cameron, Vice President of Medical Management at MVP Health Care. “The critical insight and knowledge gained by providing prescription medication monitoring, will allow physicians to more adequately assess a patient’s progress and maintenance of chronic conditions.”
“This agreement will improve clinical care for MVP’s members being treated with powerful prescription medications,” said Todd Gardner, Chief Operating Officer of Ameritox. “With more medications being prescribed than ever, regular monitoring will help Ameritox and MVP Health Care recommend solutions that prevent the tragedy caused by medication misuse, abuse and diversion.”
National data shows deaths from incorrect use of prescription medications are on the rise. According to the Centers for Disease Control and Prevention, one person dies every 19 minutes from prescription drug abuse in the U.S. In 29 states, more people died in 2013 from drug overdosing than in car accidents according to Trust for America’s Health.
For more information on national prescription drug abuse, please visit: http://www.ameritox.com/national-prescription-drug-report/.

About MVP Health Care

Founded in 1983, MVP Health Care is a community-focused, not-for-profit health insurer serving members in the states of New York, Vermont and New Hampshire. Through its operating subsidiaries, MVP Health Care provides fully insured and self-funded employer health benefits plans, dental insurance, and ancillary products such as flexible-spending accounts, to 700,000 members, with a regional network of 19,000 health care providers, as well as providing access to a national network of more than 500,000 health care providers. For more information, visit www.mvphealthcare.com, on Facebook at www.facebook.com/mvphealthcare, and on Twitter at @MVPHealthCare.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.
Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox
Watch Ameritox on YouTube: www.youtube.com/ameritox

Contact:
Lon Wagner, Ameritox
Office: 336-387-7742

Rogers kicks off ‘I Am UNITE’ scholarship

May 15, 2013 / Ameritox

Operation UNITE formally unveiled its new “I Am UNITE” scholarship program Friday morning in Rockcastle County.

Students, parents, civic leaders, elected officials and business leaders packed the Rockcastle County High School gymnasium for the ceremony – one of many to be conducted in the next few weeks to award scholarships to 19 graduating seniors across southern and eastern Kentucky….

In addition to the “I Am UNITE” scholarships, Bradshaw and Avery were awarded $5,000 scholarships through a UNITE Foundation donation by Ameritox, a company that provides physicians with drug monitoring and reporting services.

>Read more

Methamphetamine Urine Toxicology: An In-depth Review

November 30, 2012 / Ameritox

The following appeared in Practical Pain Management and was authored by Ameritox’s Michael DeGeorge, Jr., PharmD and John Weber.

When a patient’s urine drug screen tests positive for methamphetamine by mass spectrometry, the result has serious implications for the patient and the provider. Determining the source of the methamphetamine is an important next step and is not always as straightforward as it appears.

>Read More

Bath Salts – Designer Drug Danger

October 1, 2012 / Ameritox

From Brain Blogger: The media has been abuzz in recent weeks about “bath salts” — but they’re not writing headlines about the scented crystals used for bathing or Epsom salts. Bath salts are the latest designer street drug to raise alarm bells across Europe and the United States. Marketed falsely under benign-sounding names that also include “research chemicals” or “plant food,” these substances are part of a dangerous new class of drugs called synthetic cathinones.

>Read the Full Story

LEIDER: ‘Bath salt’ craze poses new threat

September 28, 2012 / Ameritox

From Washington Times: A New York man was just arrested for the second time in four days on charges of larceny, drug possession and endangering a child. The police found him standing on a mobile home, tossing his personal possessions and yelling that there was a man trapped in his chimney.

In Pennsylvania, just two days after giving birth, a woman stripped, fought off her nurses and tried to bite a police officer. In Arizona, a naked man recently crashed a stolen jeep. In New York, a woman attacked a police officer, yelling, “I want to kill someone and eat them.”

This is what the origin of a man-made drug scourge looks like. These bizarre criminal acts were committed by people high on “bath salts” — an infamous synthetic designer drug sweeping the nation.

>Read the Full Story

One Third of Prescribed Opioids Missing in Urine

September 13, 2012 / Ameritox

From MedScape: Tests show 35% of urine samples are lacking evidence that prescribed medications were actually taken.

>Read the Full Story

Ameritox invests in depression blood test with Ridge licensing deal (Clinica)

April 5, 2012 / Ameritox

From Clinica: Pain medication monitoring specialist Ameritox is branding out into depression after signing a deal that will allow it to sell Ridge Diagnostics’ blood test for major depressive disorder, MDDScore, to primary care and pain physicians. Ridge claims the product is the first clinically-available blood test for depression — albeit to a very limited market for now — and CEO Lonna Williams told Clinica the company hasn’t “seen anything else on the horizon.”

>Read the full story

Also, read the press release from Ameritox.com: Ridge Diagnostics, Inc. and Ameritox Ltd. Enter Into Licensing Agreement for Depression Biomarker Blood Test

Dr. Leider on Ameritox’s Support of New Expert Consensus Panel (Pain Live)

March 15, 2012 / Ameritox

From Pain Live: Harry L. Leider, MD, MBA, FACPE, Chief Medical Officer and Senior Vice President, Ameritox medication monitoring solutions, discusses Ameritox’s support of a consensus panel that looked at the use of urine drug monitoring.

>Read More